Canada markets open in 8 hours 16 minutes

XNCR Jun 2024 25.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.10000.0000 (0.00%)
As of 10:53AM EDT. Market open.
Full screen
Previous Close0.1000
Open0.1000
Bid0.0000
Ask0.0000
Strike25.00
Expire Date2024-06-21
Day's Range0.1000 - 0.1000
Contract RangeN/A
Volume1
Open InterestN/A
  • Business Wire

    Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

    PASADENA, Calif., June 13, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase 1 clinical development in hematologic cancers. In 2021, Xencor entered a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize

  • Simply Wall St.

    Xencor First Quarter 2024 Earnings: Misses Expectations

    Xencor ( NASDAQ:XNCR ) First Quarter 2024 Results Key Financial Results Revenue: US$12.8m (down 33% from 1Q 2023). Net...

  • GuruFocus.com

    Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates

    Comprehensive Analysis of Financial Performance and Strategic Initiatives